Radiotherapy and immune checkpoint blockades : a snapshot in 2016

• 발행기관: 대한방사선종양학회
• 저자명: Taeryool Koo In Ah Kim
• 간행물 정보: 『대한방사선종양학회지』제34권 제4호, 250~259쪽, 전체 10쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 2016.12.30

영문 초록

Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.

목차

Abstract

Introduction

RT Combined with Checkpoint Blockades : Preclinical Data

RT Combined with Checkpoint Blockades : Clinical Data

How to Combine RT with Checkpoint Blockades?

Ongoing Trials and Future Perspectives

Conclusion

Conflict of Interest

Acknowledgments

References

키워드

Radiotherapy Immune checkpoint blockades Cytotoxic T-lymphocyte antigen-4 Programmed cell death 1 receptor